sorry, we can't preview this file

...but you can still download Breast_Cancer_Supplemental_Data.docx

Breast_Cancer_Supplemental_Data.docx (26.91 kB)

Real-world outcomes for patients with metastatic endocrine–responsive breast cancer, with palbociclib-based combinations - supplementary material

figure

posted on 2023-08-02, 08:49 authored by Sarah Sharman Moser, Orr Friedman Mazursky, Hadas Shalev, Lior Apter, Gabriel Chodick, Nava Siegelmann-Danieli

Supplemental Figure 1: Time on treatment by last Palbociclib dose, n=559.

Funding

Pfizer Pharmaceuticals, Israel, (Grant / Award Number:)

History

Usage metrics

Keywords

CDK4/6 inhibitors HR+/HER2- breast cancer observational study palbociclib

Licence

CC BY-NC-ND 4.0